抗前蛋白转化酶枯草溶菌素9单克隆抗体临床研究进展
Chinese Pharmaceutical Journal(2015)
Abstract
系统查阅近年来抗前蛋白转化酶枯草溶菌素9(proprotein convertase subtilisin/kexin type 9,PCSK9)单克隆抗体(单抗)治疗高胆固醇血症的临床研究,分析和归纳其结果发现,在Ⅰ,Ⅱ,Ⅲ期临床试验中,抗前蛋白转化酶枯草溶菌素9单抗与安慰剂或依折麦布相比,可降低高胆固醇血症患者低密度脂蛋白胆固醇(low-density lipoprotein-cholesterol,LDL-C) 50%~ 60%,总体不良反应较少.抗前蛋白转化酶枯草溶菌素9单抗治疗高胆固醇血症的有效性和安全性已得到短期(最长52周)临床研究证实.目前正在进行扩大的Ⅲ期临床实验以评估长期用药的安全性和有效性,以及是否具有心血管疾病的保护作用.
MoreKey words
proprotein convertase subtilisin/kexin type 9,lipid lowering drug,low-density lipoprotein-cholesterol,cardiovascular disease,antibody
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined